Meta-analysis of new treatment strategies for metastatic colorectal cancer (Retraction in: Journal of the College of Physicians and Surgeons Pakistan (2009) 19:1 (56))

Journal of the College of Physicians and Surgeons Pakistan

Volumn 14, Issue 10, 2004, Pages 638-642

  Parvez, Tariq ^a   Mahrous, Abdul Rehman Saleh ^a   Fawazi, Adel ^a  

^a KING FAHAD HOSPITAL   (Saudi Arabia)

Author keywords

Anti angiogenesis factors; Chemotherapy; Epidermal growth factor blockers; Farnesyltransferase inhibitors (FTIs); Metastatic colorectal carcinoma; Tyrosine kinase inhibitors

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DIHYDROPYRIMIDINE DEHYDROGENASE; DNA TOPOISOMERASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; INTERFERON; IRINOTECAN; METHOTREXATE; OXALIPLATIN; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RALTITREXED; THALIDOMIDE; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR; TIPIFARNIB; UNINDEXED DRUG;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DRUG ABSORPTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; ENZYME INHIBITION; HAND FOOT SYNDROME; HUMAN; LIVER METASTASIS; META ANALYSIS; MOLECULAR MIMICRY; NEPHROTOXICITY; NEUTROPENIA; TREATMENT PLANNING;

ALKYL AND ARYL TRANSFERASES; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FARNESYLTRANSTRANSFERASE; FLUOROURACIL; HUMANS; ORGANOPLATINUM COMPOUNDS; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 7244227961     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5-26.
2. Midgley R, Kerr D. Colorectal cancer. Lancet 1999; 353: 391-9.
3. Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 2000; 321: 531-5.
4. Moertel CG. Chemotherapy for colorectal cancer. N Engl J Med 1994; 330: 1136-42.
5. Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chon TC, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996; 14:709-15.
6. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianea R, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-12. Erratum in Lancet 1998 352 (9140): 1634.
7. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasck P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-7. Erratum in: Lancet 2000 355 (9212): 1372.
8. Raymond E, Buquet-Fagot C, Djelloul S, Mester J, Cvitkover E, Allain P, et al. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drug 1997; 8: 876-5.
9. Andre T, Louvet C, Raymond E, Tournigand C, de Gramont A. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann Oncol 1998; 9: 1251-3.
10. de Gramont A, Figer A, Seymour M, Honierin M, Honissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47.
11. Maindrault-Goebel F, Louvet C, Andre T, Carolar E, Lotz JP, Molitor JL, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 1999; 35: 1338-42.
12. Maindrault-Goebel F, de Gramont A, Louvet C, Carolar E, Mabro M, Artum P, et al. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 2001; 37: 1000-5.
13. Rothenberg M, Oza A, Burger B. Phase III trial of bolus + infusional 5-FU/leucovorin vs. oxaliplatin vs. the combination in patients with recurrent metastatic colorectal cancer following irinotecan, bolus 5-FU and leucovorin: interim results. Presented at the 27th European Society for Medical Oncology. Nice, France. 2002; October 18-22.
14. Tournigand C, Louvet C, Quinaux E. FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): final results of a phase III study (abstract). Proc Annu Meet Am Soc Clin Oncol 2001; 20: 494.
15. Macdonald JS. Oral fluoropyrimidines: a closer look at their toxicities. Am J Clin Oncol 1999; 22: 475-80.
16. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-Analysis Group in Cancer. J Clin Oncol 1998; 16: 301-8.
17. Van Cutsem E, Findlay M, Osterwalder B, Kocha W, Dalley D, Pazdur R, et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 2000; 18: 1337-45.
18. Twelves C, Boyer M, Findlay M, Cassidy J, Weitzel C, Barker C, et al. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer 2001; 37: 597-604.
19. Hoff PM, Ansari R, Batist G, Cox J, Kochar W, Kuperminc M, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19: 2282-92.
20. Kerr DJ, Ten Bokkel Huinink WW, Ferry DR, et al. A phase I/II study of CPT-11 in combination with capecitabine as first line chemotherapy for metastatic colorectal cancer (MCRC) (abstract). Proc Annu Meet Am Soc Clin Oncol 2002; 21:643.
21. Maughan TS, James RD, Kerr D. Preliminary results of a multicentre randomised trial comparing 3 chemotherapy regimens (de Gramont, Lokich and Raltitrexed) in metastatic colorectal cancer (abstract). Proc Annu Meet Am Soc Clin Oncol 1999; 18: 262.
22. Grothey A, Schmoll HJ. New chemotherapy approaches in colorectal cancer. Curr Opin Oncol 2001; 13: 275-86.
23. Adam R, Avisar E, Ariche A, Giachetti S, Azonlay D, Castaing D, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal metastases. Ann Surg Oncol 2001; 8: 347-53.
24. Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coil DG, et al. Liver resection for colorectal metastases. J Clin Oncol 1997; 15: 938-46.
25. Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10: 663-9.
26. Lorenz M, Muller HH, Schramm H, Gassel HJ, Ran HG, Ridwelski K, et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 1998; 228 756-62.
27. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropul NJ, Novotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-5.
28. Giantonio B, Levy D, Catalano PJ, O'Dwyer PJ, Benson AB III. Incorporating angio-genesis inhibition with bevacizumab (anti-VEGF) into frontline chemotherapy with irinotecan (CPT-11) fluorouracil and leucovorin (FU/LV) for advanced colorectal cancer (ADVCRC): a toxicity analysis of ECOG study E2200. Program and abstracts of the American Society, 38 Annual meeting; May 18-21, 2002 Orlando, Florida Abstract 503 of cancer oncology.
29. Govindarajan R, Heaton KM, Broadwater R, Zeithin A, Lang NP, Hauer Jenson M. Effect of thalidomide on gastrointestinal toxic effects of irinotecan. Lancet 2000; 356: 566-7.
30. Govindarajan R, Maddox A, Safan M. The efficacy of thalidomide and irinotecan in metastatic colorectal carcinoma (phase II study). Proc Annu Meet Am Soc Clin Oncol 2002; 21: 2222.
31. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001; 19(suppl): 32S-40S.
32. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 2002; (7 suppl 4): 31-9.
33. Baselga J, Norton L, Masui H, Pandiellar A, Coplan K, Miller WH Jr, et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993; 85: 1327-33.
34. Sal tz L, Meropol NJ, Loehrer PJ, Waksal H, Weedle MN, Mayer RJ, et al. Single-agent IMC-C225 (Erbitux)™ has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Program and abstracts of the American Society of Clinical Oncology, 38th Annual Meeting; May 18-21, 2002; Orlando, Florida. Abstractt 504.
35. Ferry D, Hammond L, Ranson M. Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: final results from a phase I study. Proc Annu Meet Am Soc Clin Oncol 2000; 19: 5E. Abstract.
36. Braun A, Dirschl O, Hilgerl R, Lindtner B, Schleucherl N, Seeberl S, et al. Preclinical rationale for a combined treatment with irinotecan and the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 (Iressa) in irinotecanrefractory human colon cancer. Presented at the 14th EORT C-NCI-AACR Symposium on molecular targets and cancer therapeutics; November 19-22, 2002; Frankfurt, Germany. (abstract 525).
37. Hunt S. Technology evaluation: IMC-IC1, ImClone systems. Curr Opin Mol Ther 2001; 3: 418-24.
38. Blanke CD, Benson AB III, Dragovich T. A phase II trial of celecoxib (CX), irinotecan (I), 5-fluorouracil (5FU), and leucovorin (LCV) in patients (pts) with unresectable or metastatic colorectal cancer (CRC) (abstract). Proc Annu Meet Am Soc Clin Oncol 2002; 21: 505.
39. Gumgumji A, Dawood T, Parvez T. Cox-2 specific inhibitors in cancer and pre-cancerous lesions. J Coll Physicians Surg Pak 2003; 13: 361-6.
40. Cunningham D, de Gramont A, Scheithauer W. Randomized double-blind placebo-controlled trial of the farnesyltransferase inhibitor R115777 (Zarnestra) in advanced refractory colorectal cancer (abstract). Proc Annu Meet Am Soc Clin Oncol 2002; 21: 502.
41. 100. Lenz HJ, Danenberg KD, Leichman CG, Florentine B, Johnston PG, Groshen S, et al. p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. Clin Cancer Res 1998; 4: 1227-34.
42. Johnston PG, Benson AB 3rd, Catalano P, Rao MS, O'Dwyer PJ, Allegrar CJ. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. J Clin Oncol 2003; 21 815-9.
43. Leichman C. Predictive and prognostic markers in gastrointestinal cancers. Curr Opin Oncol 2001; 13: 291-99.
44. Gamelin E, Boisdron-Celle M, Guerin-Meyer V, Delvar R, Lortholany A, Genevieni F, et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining Optimal 5-FU dosage. J Clin Oncol 1999; 17: 1105-10.
45. Zhang W, Stoehlmacher J, Park DJ. A polymorphic dinucleotide repeat in intron 1 of EGFR (epithelial growth factor receptor) gene is associated with clinical response to platinum based chemotherapy in patients with advanced colorectal disease. Program and abstracts of the American Society of Clinical Oncology 38th Annual Meeting; May 18-21, 2002; Orlando, Florida. (abstract 533).
46. Ribic CM, Sargent DJ, Moore MJ. Tumor microsatellite instability (MSI) and the benefit of 5-FU based chemotherapy in stage II & III colon cancer: a pooled molecular reanalysis of randomized chemotherapy trials. Program and abstracts of the American Society of Clinical Oncology 38th Annual Meeting; May 18-21, 2002; Orlando, Florida. (abstract 509).
47. Lenz H-J, Park DJ, Zhang Wu. A multivariate analysis of genetic markers for clinical response to 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. Program and abstracts of the American Society of Clinical Oncology, 38th Annual Meeting; May 18-21, 2002; Orlando, Florida. (abstract 513).